Fouad R, Elsharkawy A, Abdel Alem S, et al. - In this investigation, researchers illustrated changes in serum α-fetoprotein (AFP) levels, widely used as a serological marker for hepatocellular carcinoma, in patients treated with a direct-acting antiviral agent (DAA)-based therapy for chronic hepatitis C and their relationship to parameters of response and liver fibrosis. The study sample consisted of 456 chronic hepatitis C virus patients who received different DAAs-based treatment regimens. The data presented in this work showed a statistically significant improvement in serum transaminases, albumin, transient elastography values, and fibrosis scores at SVR24. According to findings, DAAs-based regimens are very effective for antiviral therapy in patients with chronic hepatitis C and result in better serum AFP levels. A significant association was found between changes in AFP and liver fibrosis parameters at SVR24.